NRx Pharma rises as pain treatment drug human trials gets FDA approval

NRX Pharmaceuticals

02/10/2023 12:31

** Shares of drug developer NRx Pharmaceuticals Inc  NRXP.O 
rise 8.2% to 28 cents premarket   
    ** Says the U.S. Food and Drug Administration (FDA) had
cleared human trials of its experimental drug to treat chronic
pain  
     ** Eyes registrational studies for the drug candidate,
NRX-101, in 2024  
    ** Company also plans to seek "Fast Track" and "Breakthrough
Therapy" designations while awaiting near-term results of Dept
of Defense-funded trial
    ** FDA's "fast track" and "breakthrough therapy" tags are
intended to expedite development and review of drug candidates
being developed to treat serious conditions or unmet medical
need
    ** NRX-101, a combination of D-cycloserine and lurasidone,
is also being developed for suicidal treatment resistant bipolar
depression and post-traumatic stress disorder     
    ** Up to last close, stock down ~76.6% YTD 

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))